| Hetlioz (tasimelteon) / Vanda |
2015-003198-14: A multicenter, randomized, double-blind, placebo-controlled, parallel study to investigate the efficacy and safety of multiple oral doses of tasimelteon and matching placebo in travelers with Jet Lag Disorder |
|
|
| Ongoing | 3 | 400 | Europe | Tasimelteon (HELTLIOZ®), VEC-162, Capsule, HELTLIOZ® | Vanda Pharmaceuticals Inc, Vanda Pharmaceuticals Inc | Jet Lag Disorder (JLD), Not possible to specify | | | | |
NCT01218789 / 2010-020912-12: Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception |
|
|
| Active, not recruiting | 3 | 140 | Europe | tasimelteon, VEC-162 | Vanda Pharmaceuticals | Non 24 Hour Sleep Wake Disorder | 12/24 | 12/24 | | |
2021-005475-40: A multicenter, double-blind, randomized study to evaluate the effects of tasimelteon vs. placebo in participants with Delayed Sleep-Wake Phase Disorder (DSWPD) |
|
|
| Not yet recruiting | 3 | 300 | Europe | Tasimelteon, VEC-162, Capsule, hard | Vanda Pharmaceuticals Inc., Vanda Pharmaceuticals Inc. | Delayed Sleep-Wake Phase Disorder (DSWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT05361707: Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances |
|
|
| Recruiting | 3 | 100 | US | Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension | Vanda Pharmaceuticals | Autism Spectrum Disorder, Sleep Disorder, Neurological Disorder, Sleep Disturbance | 07/25 | 07/25 | | |
NCT04652882: Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) |
|
|
| Recruiting | 3 | 300 | Europe, US, RoW | Tasimelteon, Placebo | Vanda Pharmaceuticals | Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm, Chronobiology Disorders | 12/24 | 12/25 | | |
NCT06323655: Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy Subjects |
|
|
| Completed | 1 | 48 | Canada | Tasimelteon, Active Control Placebo, Tasimelteon Placebo, Active Control | Vanda Pharmaceuticals | Healthy Volunteers | 08/18 | 08/18 | | |
NCT05572281: Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers |
|
|
| Completed | 1 | 36 | US | Tasimelteon Oral Capsule, Tasimelteon Oral Suspension | Vanda Pharmaceuticals | Healthy | 06/22 | 06/22 | | |
RBD, NCT05922995: The Effects of Tasimelteon in Participants With REM Behavior Disorder |
|
|
| Not yet recruiting | 1 | 20 | US | Tasimelteon, Hetlioz | Brigham and Women's Hospital, Vanda Pharmaceuticals | REM Behavior Disorder | 09/26 | 12/28 | | |
